Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer

Abstract

Background:The aim of our study was to evaluate the prognostic role of immunological microenvironnement in stage II–III CRC patients.Methods:We constructed a tissue microarray from 196 consecutive patients with stage II–III CRC and compared CD3, CD4, CD8, CD57, CD68, CXCL9/MIG, CXCL13, and PPARγ immunoreactivity in tumour samples and their matched non-tumour tissue. We assessed their association with relapse-free survival (RFS; primary endpoint) and overall survival (OS) in multivariate Cox models.Results:Low densities of CD57+ and CD68+ tumour-infiltrating cells (TIC) independently predicted worse outcomes. A prognostic score combining CD57 (+, > vs −, ⩽2 cells per spot) and CD68 (+, >0 vs −, =0 cells per spot) TIC density discriminated CRC patients at low (CD68+/CD57+), intermediate (CD68+/CD57−), or high (CD68−/CD57−) risk, with hazard ratios for the intermediate-risk and high-risk groups of 2.7 (95% confidence interval (CI): 1.3–5.8) and 9.0 (3.2–25.4) for RFS, and 2.5 (1.2–5.1) and 10.6 (3.8–29.2) for OS, respectively, as compared with the low-risk group. Corresponding 5-year survival rates (95% CI) in the low-, moderate- and high-risk groups were 84% (71–91), 65% (54–74), and 12% (2–47), respectively, for RFS, and 91% (80–96), 76% (66–84), and 25% (7–59), respectively, for OS.Conclusion:Tumour CD57+ and CD68+ TIC density assessment independently predicts survival in patients with stage II–III CRC. If validated, our score based on a quick, inexpensive, and well-established method such as point counting on diagnostic tissue sections could be used routinely as a prognostic tool in CRC patients.

Malignant peripheral nerve sheath tumor (MPNST) in the spine: a retrospective analysis of clinical and molecular prognostic factors

“…Meanwhile, we found that Ki67 LI was significantly higher in high grade MPNSTs than that in low grade ones, probably suggesting that Ki67 could help distinguish between high and low grade MPNSTs. Both SMA and CD57 were confirmed to be the prognostic factors in some other tumors [33][34][35] but rarely reported in MPNSTs. We confirmed that both SMA and CD57 were not independent factors for postoperative recurrence and overall survival.…”

Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women

“…Also, we averaged the scores across several tumor cores. Moreover, it has been argued that cell counting may be more reproducible within the tumor compared to the peritumoral area, and may also be more valuable in clinical practice (4). An additional limitation is that pathology core specimens were not available for all CRC patients in this cohort.…”

“…Additionally, we examined the association between each immune score and the mortality at different AJCC-TNM stages at diagnosis; our main interest was stages 2 and 3, due to the heterogonous prognosis within these stages. The AJCC-TNM stage variable (1-4) was previously derived for CRC patients in the IWHS studies using the SEER data on tumor extension and size, the number of lymph nodes examined, and the number of positive lymph nodes.…”

“…The survival rate for CRC is improving, but 35% of patients still die within 5 years after diagnosis (1). Decisions about treatment for CRC are based largely on the tumor-node-metastasis (TNM) staging system, but there is considerable variability of outcomes within stages (2-4). Hence, to accurately determine prognosis and optimize treatment, it is essential to establish additional factors that predict and improve the stratification of CRC patients (5, 6).…”

Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers

“…While the augmented densities of this population are associated with favorable clinical outcome in colorectal (Algars et al, 2012;Chaput et al, 2013;Forssell et al, 2007;Khorana et al, 2003;Zhou et al, 2010), gastric (Ohno et al, 2003), NSCLC (Kawai et al, 2008;Ma et al, 2010;Ohri et al, 2009;Welsh et al, 2005), HCC (Li, Qiu, et al, 2009;Zhu et al, 2008), prostate (Shimura et al, 2000), and cervical cancer (Heller et al, 2003), it has exactly the opposite association in endometrial (Č ermáková et al, 2014;Ohno et al, 2004), esophageal (Guo et al, 2007), gastric (Ishigami et al, 2003b;Kawahara et al, 2010;Osinsky et al, 2011), urothelial (Chai et al, 2008, oral Wolf et al, 2015), HCC (Ding et al, 2009;Fan et al, 2014), melanoma ( Jensen et al, 2009), breast (Campbell et al, 2011;DeNardo et al, 2011;García-Martínez et al, 2014;Leek et al, 1996;Mahmoud et al, 2012b;Zhang et al, 2013), ovarian (Salvesen & Akslen, 1999), bladder (Hanada et al, 2000;Sj€ odahl et al, 2014), NSCLC (Zhang et al, 2011), thyroid (Ryder et al, 2008), and primary CRC tumors (Bindea et al, 2013) ( Table 1 and …”